Research Papers
This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.
Displaying 185 papers
Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
6/2009 - Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman, MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother. 2009 Sep;53(9):3720-5. doi: 10.1128/AAC.00106-09.
Acid Resistance in Mycobacterium tuberculosis
5/2009 - Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09.
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis
2/2009 - Rosenthal IM, Tasneen R, Peloquin CA, et. al. Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2012 Aug; 56(8): 4331–4340. doi: 10.1128/AAC.00912-12
Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug PA-824
2/2009 - Thompson AM, Blaser A, Anderson RF, et. al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J
Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment
11/2008 - Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009 Jan;191(2):625-31. doi: 1
Estimating the market for tuberculosis drugs in industrialized and developing nations
10/2008 - Schwalbe NR, Wells WA, Geaneotes AP, et. al. Estimating the market for tuberculosis drugs in industrialized and developing nations. Int J Tuberc Lung Dis. 2008 Oct;12(10):1173-81. http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000010/a
Emerging Drugs for Active Tuberculosis
10/2008 - Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med. 2008 Oct;29(5):552-9. doi: 10.1055/s-0028-1085706.
Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
5/2008 - Wang H, Ruan Z, Li JJ, et. al. Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3168-72. doi: 10.1016/j.bmcl.2008.
Timing of Default From Tuberculosis Treatment: A Systematic Review
5/2008 - Kruk ME, Schwalbe NR, Aguiar CA. Timing of default from tuberculosis treatment: a systematic review. Trop Med Int Health. 2008 May;13(5):703-12. doi: 10.1111/j.1365-3156.2008.02042.x.
Handbook of anti-tuberculosis agents
3/2008 - Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008 Mar;88(2):85-6. doi: 10.1016/S1472-9792(08)70002-7.
The ethics of non-inferiority trials
3/2008 - Nunn AJ, Meredith SK, Spigelman MK, Ginsberg AM, Gillespie SH. The ethics of non-inferiority trials. Lancet. 2008 Mar 15;371(9616):895; author reply 896-7. doi: 10.1016/S0140-6736(08)60404-3.
Advancing the science in clinical trials for new TB drugs
2/2008 - Wells WA, Brooks A. Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Res Policy Syst. 2011 Mar 31;9:15. doi: 10.1186/1478-4505-9-15.
New tuberculosis therapeutics: a growing pipeline
8/2007 - Spigelman MK New tuberculosis therapeutics: a growing pipeline. J Infect Dis. 2007 Aug 15;196 Suppl 1:S28-34. http://jid.oxfordjournals.org/content/196/Supplement_1/S28.long. Accessed March 7, 2016
Turning the tide on tuberculosis: a combined effort
7/2007 - Spigleman M. Turning the tide on tuberculosis: a combined effort. SciDevNet. 2007 4 Jul. http://www.scidev.net/global/health/opinion/turning-the-tide-on-tuberculosis-a-combined-effor.html. Accessed March 11, 2016
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery
6/2007 - Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00008?token=00521b85a26b1174e1f7b76504c48662a2
Challenges associated with current and future TB treatment
6/2007 - Laurenzi M, Ginsberg AM, Spigelman M. Challenges associated with current and future TB treatment. Infect Disord Drug Targets. 2007 Jun;7(2):105-19. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00004?token=004e1567d370e7e442f206
Planning to improve global health: the next decade of tuberculosis control
5/2007 - Dermot Maher, Chris Dye, Katherine Floyd, et. al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ. 2007 May; 85(5): 341–347. doi: 10.2471/06.037820
Challenges in tuberculosis drug research and development
3/2007 - Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med. 2007 Mar;13(3):290-4. http://www.nature.com/nm/journal/v13/n3/full/nm0307-290.html. Accessed March 7, 2016
Antimycobacterium Agents
1/2007 - Ma Z, Ginsberg A, Spigelman M. Antimycobacterium Agents. Elsevier, Philadelphia, PA. 2007 Jan; 700-4, 719-20, 26.
Novel targets for tuberculosis drug discovery
10/2006 - Mdluli K, Spigelman M. Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol. 2006 Oct;6(5):459-67. http://www.sciencedirect.com/science/article/pii/S1471489206001354. Accessed March 7, 2016